Pelareorep

Drug Profile

Pelareorep

Alternative Names: PO-BB0209; REOLYSIN; Reovirus; Reovirus - Oncolytics Biotech; Reovirus anticancer; Reovirus antitumour; Reovirus Serotype 3 - Dearing Strain; Respiratory Enteric Orphan virus; Wild-type reovirus

Latest Information Update: 18 Apr 2017

Price : $50

At a glance

  • Originator Oncolytics Biotech
  • Developer Mayo Clinic; National Cancer Institute (Canada); National Cancer Institute (USA); Oncolytics Biotech; University of Leeds; University of Southern California
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Apoptosis stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Peritoneal cancer; Ovarian cancer; Gastric cancer; Pancreatic cancer; Fallopian tube cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Head and neck cancer
  • Phase II Brain cancer; Colorectal cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Sarcoma
  • Phase I/II Glioma
  • Phase I Multiple myeloma; Solid tumours
  • Preclinical Hepatocellular carcinoma; Viral hepatitis

Most Recent Events

  • 12 Apr 2017 Updated efficacy data from a phase II trial in Breast cancer released by Oncolytics Biotech
  • 05 Apr 2017 Efficacy and adverse events data from a phase II trial in Breast cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 31 Mar 2017 Oncolytics Biotech plans registrational study for Breast cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top